主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PDSB
#3621
PDS Biotechnology Corporation Common Stock
0.6
8
-1.45%
版块:
基础:
利润货币:
日范围
年范围
日变化
-1.45%
每月变动
-32.00%
6个月变化
-47.29%
年变化
-52.45%
前一天收盘价
0.6
9
Open
0.6
8
Bid
Ask
Low
0.6
8
High
0.6
8
交易量
6
市场
股票
医疗保健
PDSB
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
22.26 M
28.45 M
30.72 M
36.68 M
45.4 M
—
Valuation ratios
Enterprise value
18.8 M
165.23 M
252.48 M
132.3 M
32.3 M
100.08 M
Price to earnings ratio
—
-12.27
-7.43
-3.71
-1.58
-5.53
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
—
-16.61
-11.81
-4.74
-1.7
-5.85
Price to book ratio
—
3.28
6.9
6.1
3.13
4.88
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.48
-0.25
-0.53
-0.72
-0.83
-0.85
Return on equity %
0.55
-0.27
-0.93
-1.64
-1.98
-2.34
Return on invested capital %
9 999.18
-16.09 K
-23.94 K
-6 611.39
-1 706.76
-966.63
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.28
17.8
7.79
4.33
2.64
9.97
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
0.3
0.33
0.2
1
Long term debt to total equity ratio
—
—
0.52
0.75
0.48
2.84
Per share metrics
Operating cash flow per share
—
-0.49
-0.9
-1.09
-0.96
-0.77
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
2.55
2.58
1.83
1.14
3.39
Net current asset value per share
—
2.61
2.67
1.91
1.24
3.61
Tangible book value per share
—
2.47
1.54
0.84
0.52
1.62
Working capital per share
—
2.46
2.33
1.47
0.77
2.16
Book value per share
—
2.47
1.54
0.84
0.52
1.62
新闻
PDS Biotech修订三期试验方案以增加加速审批途径
PDS Biotech amends Phase 3 trial to add accelerated approval path
PDS Biotech前列腺癌研究显示9.6个月无进展生存期
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study
PDS Biotech获得癌症免疫疗法PDS0101专利
PDS Biotech secures patent for cancer immunotherapy PDS0101
PDS Biotech股价在FDA会议提供加速批准路径后飙升
PDS Biotech stock soars after FDA meeting provides accelerated approval path
PDS Biotech向FDA提交修订后的第三期癌症试验方案
PDS Biotech submits amended protocol for phase 3 cancer trial
PDS Biotech secures new patent for cancer immunotherapy in Japan
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why